Any current/future new fundraising through debt or equity?

There is a mention of new ESOP issuances planned, but these will be issued at market price and will not impact the profit and loss account significantly. (Page 6) No explicit statement or indication of any current or future fundraising through debt or equity is provided in the transcript. The company highlights a strong solvency ratio of 2.14 times, indicating a comfortable capital position without expressing any immediate need for raising capital. (Page 6 and 11) Discussion around profitability and capital adequacy suggests the company is well-positioned financially, with plans to maintain he

Any current/future capex/capital investment/strategic investment?

The transcript does not explicitly mention any specific current or future capex or capital investment plans. It highlights ongoing strategic initiatives such as increasing exclusive agent numbers and expanding partnerships with large NBFCs. There is focus on improving fraud control, negotiating hospital rates, and growing profitable business segments including retail and group insurance. Investment strategy includes increasing exposure to ETFs from 4.1% to about 7% of the portfolio. No direct mention of new technology capex; however, collaboration with a fintech firm on wellness programs integ

Future growth expectations in sales/revenue/volumes?

Star Health expects to grow faster than the health insurance industry, particularly in retail health. April 2023 premium growth is promising, with over 25% growth expected for the month. For FY2024, value growth is expected around 55%-60%, and volume growth around 40%-45%. The company aims to improve average sum assured and target more affluent customer segments. Market share in retail health is targeted to increase beyond FY2023 levels (currently at 34%). Digital initiatives and partnerships with banks and corporate agents are expected to drive growth. Agency strength is growing,

Future growth expectations in earnings/operating earnings/profits/EPS?

Company expects to sustain faster than industry growth in retail health segment, with promising early FY2024 performance (April growth over 25%). Combined operating ratio is expected to improve for FY2024, aided by price hikes, efficiency improvements, and technology-driven initiatives. ROE guidance for FY2024 is targeted at 16%-18%, up from 12.4% in FY2023 (adjusted for ESOP costs). Profit after tax for FY2023 was Rs. 619 crore (Rs. 768 crore excluding non-business costs); Q4 FY2023 PAT was Rs. 102 crore. APAT growth is expected from continued premium hikes and profitable product mix

Star Health & Allied Insurance Company LtdQ4 FY23Insurance

Star Health & Allied Insurance Company Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹532.4P/E: 37.1Market Cap: ₹31.3K CrSector: Insurance

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

N/A

Order

Yes

Capex

N/A

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Star Health expects to grow faster than the health insurance industry, particularly in retail health.
April 2023 premium growth is promising, with over 25% growth expected for the month.
For FY2024, value growth is expected around 55%-60%, and volume growth around 40%-45%.
The company aims to improve average sum assured and target more affluent customer segments.
Market share in retail health is targeted to increase beyond FY2023 levels (currently at 34%).
Digital initiatives and partnerships with banks and corporate agents are expected to drive growth.
Agency strength is growing, with addition of exclusive agents aiming to double from last year’s ~18,000.
Inclusive growth across retail and group business with focus on profitable SME groups.
Continued focus on innovative and specialized health insurance products to drive growth momentum.

Margin guidance

Category 2

Company expects to sustain faster than industry growth in retail health segment, with promising early FY2024 performance (April growth over 25%).
Combined operating ratio is expected to improve for FY2024, aided by price hikes, efficiency improvements, and technology-driven initiatives.
ROE guidance for FY2024 is targeted at 16%-18%, up from 12.4% in FY2023 (adjusted for ESOP costs).
Profit after tax for FY2023 was Rs. 619 crore (Rs. 768 crore excluding non-business costs); Q4 FY2023 PAT was Rs. 102 crore.
APAT growth is expected from continued premium hikes and profitable product mix shifts.
New product launches and expanded bancassurance tie-ups are expected to drive growth.
Price increases are ongoing, monitored by product loss ratios, to maintain profitability.
Growth strategies focus on profitable segments, including SME groups and higher sum assured products, supporting sustainable earnings expansion.

See what Star Health & Allied Insurance Company Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is a mention of new ESOP issuances planned, but these will be issued at market price and will not impact the profit and loss account significantly. (Page 6)
No explicit statement or indication of any current or future fundraising through debt or equity is provided in the transcript.
The company highlights a strong solvency ratio of 2.14 times, indicating a comfortable capital position without expressing any immediate need for raising capital. (Page 6 and 11)
Discussion around profitability and capital adequacy suggests the company is well-positioned financially, with plans to maintain healthy solvency and potentially pay dividends in the future after risk-based solvency implementation. (Page 11)
No announcements or indications regarding fresh equity or debt fundraises were made during the call.

Order book

Yes

The provided transcript pages from the Star Health and Allied Insurance Company Limited earnings call do not contain information related to the company's current or expected order book or pending orders. The discussion primarily focuses on financial performance, growth strategies, agent additions, hospital network agreements, fraud management initiatives, product mix, and operational metrics. Therefore, no details on current or expected order books or pending orders are available in the provided document pages.

See what Star Health & Allied Insurance Company Ltd management said on order book — free account, 30 seconds.

Capex plans

The transcript does not explicitly mention any specific current or future capex or capital investment plans.
It highlights ongoing strategic initiatives such as increasing exclusive agent numbers and expanding partnerships with large NBFCs.
There is focus on improving fraud control, negotiating hospital rates, and growing profitable business segments including retail and group insurance.
Investment strategy includes increasing exposure to ETFs from 4.1% to about 7% of the portfolio.
No direct mention of new technology capex; however, collaboration with a fintech firm on wellness programs integrating IoT devices into their app indicates a digital/technology focus.
ESOP issuances are planned at market price, which will not impact P&L.
Overall, emphasis is on profitable growth and operational efficiency rather than large capex or new strategic investment announcements in this transcript.

Track Star Health & Allied Insurance Company Ltd — get its next earnings analysis in your feed

How does Star Health & Allied Insurance Company Ltd rank vs peers in Insurance?

Pro feature

ThisStar Health & Allied Insurance Company Ltd

Rev 2Mar 2

See where Star Health & Allied Insurance Company Ltd sits in InsuranceSee which companies these are, and every other name in the sector.Open rankings

How does Star Health & Allied Insurance Company Ltd rank in Insurance?

Compare Star Health & Allied Insurance Company Ltd against every Insurance company (Q4 FY23) on revenue, margins and earnings-call signals.

View Insurance leaderboard →

What Star Health & Allied Insurance Company Ltd's management said in earlier quarters

Others in Insurance this season

SBI Life Insurance Company Ltd (Q2 FY27)
For the quarter ended September 30, 2026, SBI Life Insurance reported premium received from policyholders of ₹48,97,583 lakhs compared to ₹44,07,462 lakhs for…
HDFC Life Insur. (Q3 FY26)
Profit after tax (PAT) grew 7% to Rs. Key concall takeaways from HDFC Life Insurance Company Ltd's Q3 FY26 earnings call — and how it ranks against sector…
Max Financial Services Ltd (Q4 FY26)
Total APE (Annualized Premium Equivalent) for FY’26: Rs 10,502 crore, up 20% YoY from Rs 8,770 crore in FY’25 (Page 4). Key investor presentation takeaways from
ICICI Lombard (Q2 FY27)
Health insurance continues its rapid expansion, notably Retail Health with a 66.4% growth in H1 FY2027, outpacing industry growth, indicating sustained future…

Compare:vs Life Insurance vs SBI Life Insurance Company Ltd vs HDFC Life Insur.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Star Health & Allied Insurance Company Ltd Q4 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Star Health & Allied Insurance Company Ltd rank in Insurance?

Continue your research

What Star Health & Allied Insurance Company Ltd's management said in earlier quarters

Others in Insurance this season